DEDAGROUP-STEALTH
14.5.2020 08:03:12 CEST | Business Wire | Press release
Dedagroup Stealth, the tech company behind more than 60% of Italy’s best-known global fashion brands, has acquired Zedonk, the company relied on by more than 650 small fashion businesses.
Until now, smaller brands and start-ups had no access to a single, integrated solution for managing the entire product life cycle, from initial design and production, right through to multichannel distribution in retail, wholesale, marketplaces and social commerce channels, and in addition they had no access to an Enterprise Resource Planning (ERP) technology to support rapid international growth. The acquisition of Zedonk by Dedagroup Stealth fills this market gap.
Dedagroup Stealth is one of only a handful of international companies with a wide range of software solutions for the efficient and flexible management of all the production and distribution processes for fashion products across multiple channels, which has given it leadership among large and medium-sized brands.
Now, with Zedonk, Dedagroup Stealth will be a unique partner for smaller fashion companies, from the very beginning of their growth trajectory right through to international expansion.
Zedonk enables brands in their emerging phase as well as those who are established, but want to accelerate their digital transformation journeys. Its solutions include design and production management, stock inventory, purchase orders, style management as well as customer and supplier relations, with all data managed and protected in the Cloud.
As well as complementary technologies, the two companies now have a significant footprint in the UK through new headquarters in London where Dedagroup Stealth consultants already on the ground will join the Zedonk team.
Marcia Lazar, Co-founder of Zedonk , said: "We join the Dedagroup Stealth family with great enthusiasm. For us, it is the ideal strategic partner to continue on our ambitious development path. We are truly satisfied with this global operation, which has the clear objective of bringing to the fashion sector an offer that can accompany any brand in every phase of its life, from the launch to the intermediate development phase up to maturity, supporting it in the definition of processes and strategies.”
Mimmo Solida, CEO of Dedagroup Stealth , added: “For too long, many brands have struggled to find an integrated solution that helps them manage their entire supply chain. It has long been our ambition to find a partner that can support designers, small brands and fashion start-ups as they grow, with a range of solutions that support business critical focuses of fashion retailers, from supply chain to sales, that allow for internationalisation. This acquisition will bring new value to the market and, at the same time, will strongly support our expansion strategy geographically and as a business, whilst completing our product portfolio to support fashion brands from entrepreneurial start-ups to enterprise players.”
Marco Podini, Executive Chairman of Dedagroup Stealth parent company Dedagroup, commented: "I am particularly pleased by the acquisition of Zedonk because our software, which has already contributed to the growth of many important creative brands in the world, can help other small fashion companies to develop rapidly. Our support is more vital than ever now that the market has changed so drastically for companies of all sizes, made even worse in the current crisis as whole countries shut down.”
“The global fashion industry needs the right tools to capitalise on business opportunities without being overwhelmed at an organisational level. The tsunami moving from east to west, leaving behind lowered shutters and people locked indoors, will be followed by a second wave that will see everyone wanting to get back to normal. Agility, underpinned by robust digital technologies, will be the catalyst that defines business success and will fuel retail performance in markets as they reopen, starting from China. Dedagroup Stealth will be able to support brands from the very smallest up to the largest as they restart their plans for global expansion,” Podini concluded.
-ENDS-
View source version on businesswire.com: https://www.businesswire.com/news/home/20200513005645/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
